Navigation Links
One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
Date:3/2/2011

RICHMOND, Va., March 2, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that the one-for-10 reverse stock split of Insmed's Common Stock became effective as of 5:00 PM EST, on March 2, 2011, after the State Corporation Commission of the Commonwealth of Virginia accepted the amendment to Insmed's Articles of Incorporation to effect the reverse stock split.  The shareholders of Insmed approved the amendment at the Special Meeting of Shareholders held on March 1, 2011.  Insmed's common stock will start trading on a split-adjusted basis on or about market open on March 3, 2011.

Following the reverse stock split, each holder of 10 shares of Insmed Common Stock immediately prior to the effectiveness of the reverse stock split became the holder of one share of Insmed Common Stock.  Shareholders will receive a cash payment in lieu of any fractional shares of Common Stock they are entitled to receive.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to expectations regarding the anticipated benefits of the reverse stock split and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  The risks and uncertainties include, without limitation, we may be unsuccessful in developing our product candidates, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009 and Quarterly Report on Form 10-Q for the fiscal quarters ended March 31, 2010, June 30, 2010 and September 30, 2010.  Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
2. Lotus Pharmaceuticals Announces Approval of Reverse Stock Split
3. Heska Corporation Announces Stockholder Approval of Reverse Split
4. U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly
5. Bionovo Announces Reverse Stock Split
6. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
7. NOVT Corporation Completes Reverse/Forward Stock Split
8. CardioGenics Announces Reverse Stock Split
9. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
10. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
11. Otix Global, Inc. Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... -- Now in its seventh year, the Pharmaceutical ... successful at developing and commercialising innovation. ... The Index can be summarised ... two different companies in early phase, which would make the ... of each company,s performance between 2011 and 2016, the 2017 ranking sees ...
(Date:2/27/2017)... , February 27, 2017 Leading Countries, ... market is expected to grow at a CAGR of 8.9% ... expected to grow at a CAGR of 9.1% from 2016 to ... in 2027. ... this report will benefit you Read on to discover how ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in North America, today announced it would be offering some it’s exclusive product ... itself on crafting quality and unique baby clothing/feeding products, will team up with ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/25/2017)... ... , ... FCPX users now have the ability to sharpen a desired color ... users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, ... users can visually see the color range effected with ease all within Final ...
Breaking Medicine News(10 mins):